Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic

Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer.. Breast

The TAMRAD study was a phase II trial evaluating the use of everolimus in combination with tamoxifen in postmenopausal women with metastatic hormone receptor-positive,

Exemestane versus anas- trozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the

ABC, advanced breast cancer; CBR, clinical benefit rate; ET, endocrine therapy; HER2–, human epidermal growth factor receptor 2 negative; HR+, hormone receptor positive;

Table 5.1 Prevalence of adjuvant endocrine therapy (AET) adherence and persistence among Appalachian women with invasive, non-metastatic, hormone-receptor positive

Methods: The Suppression of Ovarian Function (SOFT) trial randomised premenopausal women with hormone receptor-positive breast cancer to 5 years adjuvant endocrine therapy

1,25 Treatment with neoadjuvant endocrine therapy in patients with hormone- receptor (HR) positive breast cancer is thus usually reserved for postmenopausal women with

palbociclib versus fulvestrant plus placebo for treatment of hormone- receptor-positive, HER2-negative metastatic breast cancer that pro- gressed on previous endocrine

Metabolic reprogramming of oestrogen receptor positive breast cancer in endocrine therapy resistance. PhD Course in Life Sciences and Biotechnologies XXIX cycle - Università degli

Premenopausal women with invasive breast cancer that is hormone receptor positive should be considered for adjuvant endocrine therapy regardless of lymph node status, or whether

Adjuvant endocrine therapy recommendations for premenopausal women with hormone receptor (HR) – positive breast cancer have changed on the basis of the 5-year results of the

Our findings indicate that among 21,991 hormone receptor-positive, HER2-negative, early-stage node- negative breast cancer patients who received endocrine therapy and had a

Tamoxifen is prescribed as a component of adjuvant endocrine therapy to prevent endocrine receptor-positive breast cancer recurrence, as treatment for metastatic breast cancer, and

The aim of this study was to investigate if thymidine kinase-1 (TK1), a well-known proliferation marker, could represent a valid circulating biomarker to identify hormone

NOTICE IS HEREBY GIVEN TO THE OWNERS AND LIEN HOLDERS OF THE VEHICLE LISTED BELOW THAT UNLESS REDEEMED PRIOR TO DATES LISTED OWNERS AND LIEN HOLDERS CONSTITUTE

Systems and Internet Infrastructure Security Laboratory (SIIS) Page Attack Trees Tamper Usage Data Tamper Measure- ment Tamper Stored Demand Tamper in Network Clear Logged

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor- positive breast cancer patients treated with adjuvant